Abstract:Highlights • Intracellular ROS kinetics dictates antigen-presenting mode. • Sustained TLR2 activation triggers intracellular ROS kinetics required for cross-presentation. • A scaffold vaccine enabling "retention-and-release" for sustained TLR2 activation in DCs promotes cross-presentation. • The scaffold vaccine induces robust, CD8 + T cells-mediated anti-tumor immune responses in Apc min/+ transgenic mice. Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8 + cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antigens via the major histocompatibility complex class I (MHC-I) to CD8 + T cells – a process known as cross-presentation. To achieve this goal, we develop a three-dimensional (3D) scaffold vaccine to promote antigen cross-presentation by persisted toll-like receptor-2 (TLR2) activation after one injection. This vaccine comprises polysaccharide frameworks that "hook" TLR2 agonist (acGM) via tunable hydrophobic interactions and forms a 3D macroporous scaffold via click chemistry upon subcutaneous injection. Its retention-and-release of acGM enables sustained TLR2 activation in abundantly recruited dendritic cells in situ , inducing intracellular production of reactive oxygen species (ROS) in optimal kinetics that crucially promotes efficient antigen cross-presentation. The scaffold loaded with model antigen ovalbumin (OVA) or tumor specific antigen can generate potent immune responses against lung metastasis in B16-OVA-innoculated wild-type mice or spontaneous colorectal cancer in transgenic Apc Min/+ mice, respectively. Notably, it requires neither additional adjuvants nor external stimulation to function and can be adjusted to accommodate different antigens. The developed scaffold vaccine may represent a new, competent tool for next-generation personalized cancer vaccination. Graphical abstract A scaffold vaccine that promotes antigen cross-presentation to trigger CD8 + T cell-mediated anti-tumor immune responses . In this study, we discover that the kinetics of intracellular ROS, unexpectedly, dictates the mode of antigen presentation. Persistent production in moderate dose promotes antigen cross-presentation. To create optimal intracellular ROS kinetics for lysosomal disruption and antigen escape, we design a 3D injectable scaffold for the "retention-and-release" of a TLR2 agonist glycan upon subcutaneous implantation. Installation of tunable hydrophobic interactions between the scaffold and the "hooked" agonist enables sustained TLR activation in the abundantly recruited DCs in situ , which triggers consequently efficient cross-presentation of tumor antigens. The efficacy of this novel scaffold vaccine is subsequently undergoing comprehensive evaluations in both wild-type and transgenic mice against localized, metastatic, and spontaneous tumors. Download : Download high-res image (369KB) Download : Download full-size image

Injectable Mesocellular Foam Silica Microparticles with a Dual Role of Cell‐Recruiting Scaffolds and Intracellular Delivery Vehicles for Enhanced Cancer Vaccine

Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.

Myeloid Cell‐Triggered in Situ Cell Engineering for Robust Vaccine‐Based Cancer Treatment

Enhanced Cancer DNA Vaccine via Direct Transfection to Host Dendritic Cells Recruited in Injectable Scaffold.

High Cellular Internalization of Virus-Like Mesoporous Silica Nanoparticles Enhances Adaptive Antigen-Specific Immune Responses against Cancer

Optimized Fabrication of Dendritic Mesoporous Silica Nanoparticles as Efficient Delivery System for Cancer Immunotherapy

Injectable cryogel-based whole-cell cancer vaccines

Efficient Tumor Immunotherapy through a Single Injection of Injectable Antigen/Adjuvant-Loaded Macroporous Silk Fibroin Microspheres.

Supramolecular co-assembly of self-adjuvanting nanofibrious peptide hydrogel enhances cancer vaccination by activating MyD88-dependent NF-κB signaling pathway without inflammation

Dual Adjuvant-Loaded Peptide Antigen Self-Assembly Potentiates Dendritic Cell-Mediated Tumor Immunotherapy

Enhanced Cancer Vaccination by In Situ Nanomicelle-Generating Dissolving Microneedles

Abstract 1565: Mesoporous silicon particle mediated dendritic cell based vaccine formulation showed stronger immunoresponse for the presentation of tumor antigens and adjuvant

In Situ Hydrogel Modulates cDC1‐Based Antigen Presentation and Cancer Stemness to Enhance Cancer Vaccine Efficiency

Bifunctional Fusion Membrane‐Based Hydrogel Enhances Antitumor Potency of Autologous Cancer Vaccines by Activating Dendritic Cells

A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation

Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy

Induction of antigen-specific immunity by mesoporous silica nanoparticles incorporating antigen peptides

Enhanced cancer immunotherapy by microneedle patch-assisted delivery of HBc VLPs based cancer vaccine

Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy

A single-shot prophylactic tumor vaccine enabled by an injectable biomembrane hydrogel

Cancer cell membrane proteins-encapsulated nanovaccine enhances cancer immunotherapy and prevention by provoking antigen-specific cellular immunity via the dendritic cell-targeted delivery